Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.
stocks

Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand

We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks

Ahead of earnings, is Netflix a buy, a sell, or fairly valued?

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,184.2027.30-0.30%
CAC 408,313.1217.84-0.21%
DAX 4025,352.3966.150.26%
Dow JONES (US)49,442.44292.810.60%
FTSE 10010,238.9454.590.54%
HKSE26,923.6276.19-0.28%
NASDAQ23,530.0258.270.25%
Nikkei 22554,110.50230.73-0.42%
NZX 50 Index13,695.8036.010.26%
S&P 5006,944.4717.870.26%
S&P/ASX 2008,861.7019.30-0.22%
SSE Composite Index4,112.6013.49-0.33%

Market Movers